- Home
- ORIC vs PCRX Comparison
ORIC vs PCRX Comparison
Compare ORIC & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- PCRX
- Stock Information
- Founded
- ORIC 2014
- PCRX 2006
- Country
- ORIC United States
- PCRX United States
- Employees
- ORIC N/A
- PCRX N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- ORIC Health Care
- PCRX Health Care
- Exchange
- ORIC Nasdaq
- PCRX Nasdaq
- Market Cap
- ORIC 1.1B
- PCRX 1.2B
- IPO Year
- ORIC 2020
- PCRX 2011
- Fundamental
- Price
- ORIC $14.19
- PCRX $23.00
- Analyst Decision
- ORIC Strong Buy
- PCRX Buy
- Analyst Count
- ORIC 8
- PCRX 5
- Target Price
- ORIC $16.57
- PCRX $32.40
- AVG Volume (30 Days)
- ORIC 1.6M
- PCRX 529.0K
- Earning Date
- ORIC 11-11-2025
- PCRX 11-05-2025
- Dividend Yield
- ORIC N/A
- PCRX N/A
- EPS Growth
- ORIC N/A
- PCRX N/A
- EPS
- ORIC N/A
- PCRX N/A
- Revenue
- ORIC N/A
- PCRX $705,848,000.00
- Revenue This Year
- ORIC N/A
- PCRX $7.36
- Revenue Next Year
- ORIC N/A
- PCRX $10.07
- P/E Ratio
- ORIC N/A
- PCRX N/A
- Revenue Growth
- ORIC N/A
- PCRX 2.25
- 52 Week Low
- ORIC $3.90
- PCRX $15.16
- 52 Week High
- ORIC $14.93
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- ORIC 71.68
- PCRX 27.69
- Support Level
- ORIC $13.85
- PCRX $24.31
- Resistance Level
- ORIC $14.93
- PCRX $26.05
- Average True Range (ATR)
- ORIC 0.81
- PCRX 0.75
- MACD
- ORIC 0.35
- PCRX -0.37
- Stochastic Oscillator
- ORIC 85.29
- PCRX 5.35
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.